Billy Dunn, FDA
December 9, 2020 09:57 AM ESTUpdated 11:23 AM
R&D
FDA+

Ad­vo­ca­cy group ac­cus­es FDA neu­ro chief Bil­ly Dunn of mis­con­duct in con­tro­ver­sial Bio­gen re­view, de­mands a purge and fed­er­al probe

John Carroll

Editor & Founder

Pub­lic Cit­i­zen has nev­er held back when it comes to crit­i­ciz­ing the FDA. But to­day, they’re tak­ing their typ­i­cal at­tack mode and ratch­et­ing it up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times